NeoGenomics (NEO) to Release Quarterly Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, February 18th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $173.40 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

NeoGenomics Trading Up 3.7 %

Shares of NeoGenomics stock opened at $14.42 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. The firm has a 50-day moving average of $15.70 and a 200-day moving average of $15.60. NeoGenomics has a 52-week low of $12.13 and a 52-week high of $19.11. The stock has a market cap of $1.85 billion, a PE ratio of -23.64 and a beta of 1.23.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Bank of America boosted their price target on shares of NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Jefferies Financial Group assumed coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They set a “buy” rating and a $22.00 target price for the company. Benchmark lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research report on Friday, January 10th. Finally, The Goldman Sachs Group decreased their target price on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.20.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.